
    
      This is a single site, parallel randomized, double blinded comparison of the safety,
      pharmacokinetics, and immunogenicity of a single 0.57 mg/kg dose of SYN060 to a single 0.57
      mg/kg dose of adalimumab (HumiraÂ®) reference product from North American and European
      sources. The study is open to healthy individuals on no medications that might confound the
      results of this safety study.

      A total of 90 subjects will be randomized in a 1:1:1 ratio to from a centrally generated
      randomization schedule to SYN060 or adalimumab of American or European sources resulting in
      30 subjects in each group.
    
  